Do you want to read an article? Please log in or register.
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
Lymphoma
Related content
Lung, Respiratory and Thoracic Cancer
Comparative effectiveness of first-line targeted therapies in ALK-positive non-small cell lung cancer: real-world evidence of tyrosine kinase inhibitors
Lung Cancer
Mudumba R, Liu X, Jin S, Davis IJ, Baid D, Romley JA, Nieva JJ
doi: 10.1016/j.lungcan.2026.109451
Leukemia
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation
Leuk Lymphoma
Claiborne JP, Tsai HL, Ghiaur G, Smith BD, Gojo I, DeZern AE, Ambinder AJ, Jain T, Prince GT, Gondek LP, Karantanos T, Dalton WB, Levis MJ, Webster JA
doi: 10.1080/10428194.2026.2628206
Lung, Respiratory and Thoracic Cancer
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
J Thorac Oncol
Brunetti L, Colella G, Di Fazio GR, La Cava G, Santo V, Pecci F, Rotow J, Bauman JR, Nassar AH, Adib E, Naqash AR, Tagliamento M, Ferrara R, Citarella F, Russano M, Ricciuti B, Faivre-Finn C, Hendriks LEL, Passaro A, Vincenzi B, Acker F, Derosa L, Planchard D, Aerts HJWL, Novello S, Passiglia F, Greco C, Ramella S, Cortellini A
doi: 10.1016/j.jtho.2026.103735
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
RECOMMENDED
Head and Neck Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Eur J Cancer
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A
doi: 10.1016/j.ejca.2026.116902
Breast Cancer
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Eur J Cancer
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM
doi: 10.1016/j.ejca.2025.116051
Leukemia
Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis
Leuk Lymphoma
Majrashi A, Shantsila A, Gue YX, Williams S, Lip GYH, Pettitt AR
doi: 10.1080/10428194.2026.2653123
Lymphoma
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial
J Clin Oncol
Ladetto M, Gutmair K, Tavarozzi R, Pawlikowski A, Schomaker M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Horowitz NA, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Heß G, van Meerten T, Wirths S, Herhaus P, Novak U, Dierlamm J, Hänel M, Hanoun C, Sonnevi K, Visco C, Castellino C, Lemoli RM, Zilioli VR, Boccomini C, Pott C, Klapper W, Schmidt C, Dreyling M, Hoster E, European MCL Network
doi: 10.1200/JCO-26-00705